Cellontech, a bio company specializing in regenerative medicine, is raising expectations for increased overseas sales of bio-collagen-based beauty and plastic surgery medical devices.
Cellontech, a subsidiary of SCN Engineering, announced on the 19th that it has signed a supply contract with Thailand's SDX Biotech for the collagen fillers 'TheraFill' and 'LUCIZEN.'
SDX Biotech, headquartered in Bangkok, Thailand, is a company specializing in beauty and plastic surgery medical services and operates TA-Ma-DA Clinic, one of the major medical aesthetic clinics in Thailand. Currently, the filler products handled at several local branches of TA-Ma-DA Clinic are only hyaluronic acid (HA)-based products. SDX Biotech expects significant synergy between products with the introduction of TheraFill and LUCIZEN.
TheraFill is a plastic surgery filler developed using Cellontech's proprietary bio-collagen technology, used to temporarily improve facial wrinkles. In 2010, the company received product approval from the Ministry of Food and Drug Safety for TheraFill, successfully localizing and commercializing collagen fillers for the first time in Korea. LUCIZEN is an upgraded product with a higher concentration of TheraFill to enhance efficiency.
Cellontech plans to move quickly to expand its market throughout Asia, including ASEAN, starting with the supply contract with Thailand, the largest beauty and plastic surgery market in Southeast Asia.
The company also participated in the 'Cosmoprof CBE ASEAN 2024' event held in Bangkok, Thailand, from the 13th to the 15th of this month, where it opened an exhibition booth and conducted marketing activities. This event is a large-scale B2B trade fair in the beauty and plastic surgery industry, where Cellontech showcased TheraFill and LUCIZEN to various global buyers.
A Cellontech official said, "Following last year's supply contract for TheraFill with China's Sahuan Pharmaceutical, the recognition of TheraFill has increased, leading to continuous supply and cooperation inquiries from domestic and international companies," adding, "Final negotiations for supply contracts of TheraFill and LUCIZEN with major Asian countries are currently underway."
He added, "Alongside the regenerative medicine field for joint cartilage centered on Cartizol, the overseas market expansion in the beauty and plastic surgery medical field centered on TheraFill is also accelerating, and it is expected that the driving force leading to increased sales will be expanded and strengthened."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
